Revance Therapeutics (RVNC) 10-Q 9 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Oct. 28, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-36297
Entity Registrant Name	Revance Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0551645
Entity Address, Address Line One	1222 Demonbreun Street, Suite 2000
Entity Address, City or Town	Nashville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37203
City Area Code	615
Local Phone Number	724-7755
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	RVNC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		71,794,852
Entity Central Index Key	0001479290
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 127,177	$ 333,558
Short-term investments	146,504	102,947
Accounts receivable, net	1,658	1,829
Inventories	10,192	5,876
Prepaid expenses and other current assets	8,352	5,793
Total current assets	293,883	450,003
Property and equipment, net	22,029	17,499
Goodwill	146,964	146,964
Intangible assets, net	59,491	71,343
Operating lease right of use assets	45,533	29,632
Restricted cash	5,057	3,445
Other non-current assets	8,871	1,334
TOTAL ASSETS	581,828	720,220
CURRENT LIABILITIES
Accounts payable	8,038	12,657
Accruals and other current liabilities	38,887	32,938
Deferred revenue, current	10,941	7,851
Operating lease liabilities, current	4,829	4,437
Derivative liability	3,179	3,081
Total current liabilities	65,874	60,964
Convertible senior notes	280,319	180,526
Deferred revenue, non-current	73,757	77,294
Operating lease liabilities, non-current	40,466	27,146
Other non-current liabilities	1,250	0
TOTAL LIABILITIES	461,666	345,930
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Convertible preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2021 and December 31, 2020	0	0
Common stock, par value $0.001 per share — 190,000,000  and 95,000,000 shares authorized as of September 30, 2021 and December 31, 2020, respectively; 71,838,777 and 69,178,666 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	72	69
Additional paid-in capital	1,454,947	1,500,514
Accumulated other comprehensive loss	(3)	0
Accumulated deficit	(1,334,854)	(1,126,293)
TOTAL STOCKHOLDERS’ EQUITY	120,162	374,290
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 581,828	$ 720,220

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock authorized (in shares)	5,000,000	5,000,000
Convertible preferred stock, shares issued (in shares)	0	0
Convertible preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	190,000,000	95,000,000
Common stock, shares issued (in shares)	71,838,777	69,178,666
Common stock, shares outstanding (in shares)	71,838,777	69,178,666

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue
Total revenue	$ 19,745	$ 3,835	$ 51,848	$ 4,192
Operating expenses:
Selling, general and administrative	52,782	48,183	152,385	99,013
Research and development	30,095	29,130	86,787	96,027
Amortization	3,705	2,565	10,219	3,239
Total operating expenses	92,468	80,963	264,920	199,385
Loss from operations	(72,723)	(77,128)	(213,072)	(195,193)
Interest income	84	413	266	2,868
Interest expense	(1,571)	(4,334)	(4,700)	(10,738)
Changes in fair value of derivative liability	(20)	(62)	(98)	(211)
Other expense, net	(146)	(146)	(608)	(406)
Loss before income taxes	(74,376)	(81,257)	(218,212)	(203,680)
Income tax provision	0	0	0	(100)
Net loss	(74,376)	(81,257)	(218,212)	(203,780)
Unrealized loss and adjustment on securities included in net loss	(1)	(117)	(3)	(3)
Comprehensive loss	(74,377)	(81,374)	(218,215)	(203,783)
Basic net loss	(74,376)	(81,257)	(218,212)	(203,780)
Diluted net loss	$ (74,376)	$ (81,257)	$ (218,212)	$ (203,780)
Basic net loss per share (in dollars per share)	$ (1.10)	$ (1.34)	$ (3.24)	$ (3.62)
Diluted net loss per share (in dollars per share)	$ (1.10)	$ (1.34)	$ (3.24)	$ (3.62)
Basic weighted-average number of shares used in computing net loss per share (in shares)	67,782,033	60,526,740	67,297,954	56,233,093
Diluted weighted-average number of shares used in computing net loss per share (in shares)	67,782,033	60,526,740	67,297,954	56,233,093
Product revenue
Revenue
Total revenue	$ 18,296	$ 2,819	$ 46,982	$ 2,868
Operating expenses:
Cost of service revenue (exclusive of amortization)	5,827	1,081	15,453	1,102
Collaboration revenue
Revenue
Total revenue	1,129	808	4,034	1,116
Service revenue
Revenue
Total revenue	320	208	832	208
Operating expenses:
Cost of service revenue (exclusive of amortization)	$ 59	$ 4	$ 76	$ 4

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Additional Paid-In CapitalCumulative Effect, Period of Adoption, Adjustment	Other Accumulated Comprehensive Gain (Loss)	Accumulated Deficit	Accumulated DeficitCumulative Effect, Period of Adoption, Adjustment
Beginning Balance (in shares) at Dec. 31, 2019		0	52,374,735	0		0	0
Beginning Balance at Dec. 31, 2019		$ 0	$ 52	$ 1,069,639		$ 3	$ (844,204)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)			2,588,353
Issuance of restricted stock awards and performance stock awards, net of cancellation			$ 2	(2)
Issuance of common stock in connection with at-the-market offerings (in shares)			975,000
Issuance of common stock in connection with at-the-market offerings			$ 1	15,536
Issuance of common stock upon exercise of stock options and warrants (in shares)			587,843
Issuance of common stock upon exercise of stock options and warrants			$ 1	4,804
Issuance of common stock relating to employee stock purchase plan (in shares)			48,661
Issuance of common stock relating to employee stock purchase plan				671
Shares withheld related to net settlement of restricted stock awards (in shares)			(257,492)
Shares withheld related to net settlement of restricted stock awards				(6,005)
Stock-based compensation				24,989
Equity component of convertible senior notes				108,510
Issuance of common stock in connection with the Teoxane Agreement (in shares)			2,500,000
Issuance of common stock in connection with the Teoxane Agreement			$ 3	43,397
Capped call transactions related to the issuance of convertible senior notes				(28,865)
Issuance of common stock in connection with the HintMD Acquisition (in shares)			7,770,613
Issuance of common stock in connection with the HintMD Acquisition			$ 8	$ 188,096
Unrealized gain (loss) and adjustment on securities included in net loss	$ (3)					$ (3)
Net loss	$ (203,780)						$ (203,780)
Ending Balance (in shares) at Sep. 30, 2020	66,587,713	0	66,587,713	0		0	0
Ending Balance at Sep. 30, 2020	$ 372,853		$ 67	$ 1,420,770		$ 0	$ (1,047,984)
Beginning Balance (in shares) at Dec. 31, 2019		0	52,374,735	0		0	0
Beginning Balance at Dec. 31, 2019		$ 0	$ 52	$ 1,069,639		$ 3	$ (844,204)
Ending Balance (in shares) at Dec. 31, 2020	69,178,666	0	69,178,666	0		0	0
Ending Balance at Dec. 31, 2020	$ 374,290	$ 0	$ 69	$ 1,500,514	$ (108,509)	$ 0	$ (1,126,293)	$ 9,651
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	Accounting Standards Update 2020-06 [Member]
Beginning Balance (in shares) at Jun. 30, 2020		0	57,313,556	0		0	0
Beginning Balance at Jun. 30, 2020		$ 0	$ 57	$ 1,222,271		$ 117	$ (966,727)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)			1,170,500
Issuance of restricted stock awards and performance stock awards, net of cancellation			$ 1	(1)
Issuance of common stock upon exercise of stock options and warrants (in shares)			511,049
Issuance of common stock upon exercise of stock options and warrants			$ 1	3,805
Shares withheld related to net settlement of restricted stock awards (in shares)			(178,005)
Shares withheld related to net settlement of restricted stock awards	$ (4,493)
Stock-based compensation				11,092
Issuance of common stock in connection with the HintMD Acquisition (in shares)			7,770,613
Issuance of common stock in connection with the HintMD Acquisition			$ 8	$ 188,096
Unrealized gain (loss) and adjustment on securities included in net loss	(117)					$ (117)
Net loss	$ (81,257)						$ (81,257)
Ending Balance (in shares) at Sep. 30, 2020	66,587,713	0	66,587,713	0		0	0
Ending Balance at Sep. 30, 2020	$ 372,853		$ 67	$ 1,420,770		$ 0	$ (1,047,984)
Beginning Balance (in shares) at Dec. 31, 2020	69,178,666	0	69,178,666	0		0	0
Beginning Balance at Dec. 31, 2020	$ 374,290	$ 0	$ 69	$ 1,500,514	$ (108,509)	$ 0	$ (1,126,293)	$ 9,651
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)			1,136,221
Issuance of restricted stock awards and performance stock awards, net of cancellation			$ 1	(1)
Issuance of common stock in connection with at-the-market offerings (in shares)			761,526
Issuance of common stock in connection with at-the-market offerings			$ 1	21,553
Issuance of common stock upon exercise of stock options and warrants (in shares)			921,376
Issuance of common stock upon exercise of stock options and warrants			$ 1	12,823
Issuance of common stock relating to employee stock purchase plan (in shares)			91,562
Issuance of common stock relating to employee stock purchase plan				2,206
Shares withheld related to net settlement of restricted stock awards (in shares)			(250,574)
Shares withheld related to net settlement of restricted stock awards				(6,944)
Stock-based compensation				$ 33,305
Unrealized gain (loss) and adjustment on securities included in net loss	(3)					$ (3)
Net loss	$ (218,212)						$ (218,212)
Ending Balance (in shares) at Sep. 30, 2021	71,838,777		71,838,777	0		0	0
Ending Balance at Sep. 30, 2021	$ 120,162		$ 72	$ 1,454,947		$ (3)	$ (1,334,854)
Beginning Balance (in shares) at Jun. 30, 2021		0	71,798,624	0		0	0
Beginning Balance at Jun. 30, 2021		$ 0	$ 72	$ 1,446,643		$ (2)	$ (1,260,478)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)			99,965
Issuance of common stock in connection with at-the-market offerings				(70)
Issuance of common stock upon exercise of stock options and warrants (in shares)			41,900
Issuance of common stock upon exercise of stock options and warrants				314
Shares withheld related to net settlement of restricted stock awards (in shares)			(101,712)
Shares withheld related to net settlement of restricted stock awards				(2,694)
Stock-based compensation				$ 10,754
Unrealized gain (loss) and adjustment on securities included in net loss	(1)					$ (1)
Net loss	$ (74,376)						$ (74,376)
Ending Balance (in shares) at Sep. 30, 2021	71,838,777		71,838,777	0		0	0
Ending Balance at Sep. 30, 2021	$ 120,162		$ 72	$ 1,454,947		$ (3)	$ (1,334,854)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Payments of stock issuance costs	$ 337
Follow On Offering
Payments of stock issuance costs	$ 44

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (74,376)	$ (81,257)	$ (218,212)	$ (203,780)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			32,513	24,574
Depreciation and amortization			14,434	5,931
Amortization of debt discount and issuance costs			935	7,576
Amortization of discount on investments			(16)	(1,351)
Other non-cash operating activities			140	474
Non-cash in-process research and development			0	11,184
Changes in operating assets and liabilities:
Accounts receivable			171	(2,492)
Inventories			(4,316)	(3,976)
Prepaid expenses and other current assets			5,141	(1,254)
Operating lease right of use assets			(15,901)	1,085
Other non-current assets			(7,537)	515
Accounts payable			(4,578)	147
Accruals and other liabilities			5,784	17,142
Deferred revenue			(447)	29,883
Operating lease liabilities			13,712	(1,846)
Other non-current liabilities			1,250	0
Net cash used in operating activities			(176,927)	(116,188)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments			(178,588)	(239,821)
Finance lease prepayments			(7,700)	0
Purchases of property and equipment			(6,018)	(1,890)
Proceeds from maturities of investments			135,000	246,500
Proceeds from sale of investments			0	16,969
Cash paid for HintMD Acquisition, net			0	(818)
Purchase of intangible assets			0	(118)
Net cash provided by (used in) investing activities			(57,306)	20,822
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock in connection with at-the-market offerings, net of commissions			21,706	0
Proceeds from the exercise of stock options, common stock warrants and employee stock purchase plan			15,029	5,476
Taxes paid related to net settlement of restricted stock awards			(6,944)	(6,005)
Payment of offering costs			(327)	(337)
Proceeds from issuance of convertible senior notes			0	287,500
Proceeds from issuance of common stock in connection with offerings, net of commissions and discount			0	15,581
Payment of capped call transactions			0	(28,865)
Payment of convertible senior notes transaction costs			0	(9,190)
Net cash provided by financing activities			29,464	264,160
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH			(204,769)	168,794
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period			337,003	171,890	$ 171,890
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period	$ 132,234	$ 340,684	132,234	340,684	$ 337,003
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Property and equipment purchases included in accounts payable and accruals			1,206	336
Internally developed software capitalized from stock-based compensation			792	415
Issuance of common stock and awards assumed in connection with the HintMD Acquisition			0	188,104
Issuance of common stock in connection with the Teoxane Agreement			$ 0	$ 43,400

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Summary of Significant Accounting Policies	The Company and Summary of Significant Accounting Policies The Company Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and are pursuing United States (“U.S.”) regulatory approval. We are also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar (frown) lines, forehead lines and crow’s feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, we own a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to Teoxane SA (“Teoxane”)’s line of Resilient Hyaluronic Acid® (“RHA®”) Collection of dermal fillers, the first and only range of U.S. Food and Drug Administration (the “FDA”)-approved fillers for correction of dynamic facial wrinkles and folds, and the OPUL™ Relational Commerce Platform (“OPUL™”). We have also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX® (“an onabotulinumtoxinA biosimilar”), which would compete in the existing short-acting neuromodulator marketplace. Since inception, we have devoted substantial efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, the onabotulinumtoxinA biosimilar, and the commercial launch of our products and services. As a result, we have incurred losses and negative cash flows from operations. We have not generated substantial revenue to date, and will continue to incur significant research and development, sales and marketing, and other expenses related to our ongoing operations. Liquidity and Going Concern Assessment For the three and nine months ended September 30, 2021, we had a net loss of $74.4 million and $218.2 million, respectively. As of September 30, 2021, we had working capital surplus of $228.0 million and an accumulated deficit of $1.3 billion. In recent years, we have funded our operations primarily through the sale of common stock, convertible senior notes, payments received from collaboration arrangements, and sales of the RHA® Collection of dermal fillers. As of September 30, 2021, we had capital resources of $273.7 million consisting of cash, cash equivalents, and short-term investments. On October 15, 2021, the FDA issued a Complete Response Letter (“CRL”) regarding our BLA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines. The FDA indicated it was unable to approve the BLA in its present form due to deficiencies related to the FDA’s onsite inspection at our manufacturing facility. As a result, the potential commercial launch of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines has been delayed. Absent deferring and reducing certain costs previously planned as well as other mitigating actions, the commercial launch delay and its impact on our capital resources would raise substantial doubt with respect to our ability to meet our obligations to continue as a going concern within one year following the filing of this Report. Despite the delay in approval and in consideration of the cash preservation measures management has identified, we believe that our existing cash, cash equivalents, and short-term investments will allow us to fund our operations for at least 12 months following the filing of this Report while we continue to work with the FDA for the potential approval of our BLA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines. Our plan to preserve cash in order to fund our operations for at least 12 months following the filing of this Report includes, but is not limited to: pausing non-critical hires; deferring the Phase 3 clinical program for upper limb spasticity and other therapeutics pipeline activities; and deferring international regulatory and commercial investment for DaxibotulinumtoxinA for Injection. Our plans contemplate continued support for our partnership with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. The condensed consolidated financial statements have been prepared on a going-concern basis. The condensed consolidated financial statements do not include any adjustments relating to any of the foregoing uncertainties. Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. Our condensed consolidated balance sheet for the year ended December 31, 2020 was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2021, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (the “SEC”), on February 25, 2021. Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. All intercompany transactions have been eliminated. Use of Estimates & Risks and Uncertainties The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, the fair value of assets and liabilities assumed in business combinations, the incremental borrowing rate used to measure operating lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, the period of benefit associated with deferred costs, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals for clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, the fair value of derivative liability, and income taxes. The full extent of the impact of the COVID-19 pandemic on the Company’s future operational and financial performance is currently uncertain. The ongoing COVID-19 pandemic has caused a global slowdown of economic activity which has negatively impacted consumer spending, including with respect to our current and potential customers, while also disrupting sales channels and marketing activities. The extent to which the COVID-19 pandemic will further directly or indirectly impact our business, results of operations, financial condition, and liquidity will depend on future developments that are highly uncertain, including variant strains of the virus and the degree of their vaccine resistance and as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects. The FDA was previously unable to conduct the required inspection of our manufacturing facility in Northern California, due to the FDA’s travel restrictions associated with the COVID-19 pandemic. Although the FDA inspection process has taken place and we have responded to the FDA’s observations from the inspection, we cannot be certain of how long it will take to remediate deficiencies identified by the FDA during the inspection and respond to the FDA or how quickly or successfully the regulatory approval process will move following our remediation of the deficiencies and our response to the FDA or the future impact of the COVID-19 pandemic on the submissions related to DaxibotulinumtoxinA for Injection in indications outside of glabellar (frown) lines, the progress of clinical trials, supplies and sales of the RHA® Collection of dermal fillers, demand for our products and other aspects of our operations. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements. Recently Adopted Accounting Pronouncement In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible debt instruments by removing certain requirements to separately account for conversion options embedded in debt instruments that are not required to be accounted for as derivative instruments. ASU 2020-06 also updates and improves the consistency of earnings per share calculations for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. On January 1, 2021, we adopted ASU 2020-06 using the modified retrospective method, and the adoption did not have any impact on our consolidated balance sheets as of December 31, 2020. As a result of the adoption, on January 1, 2021, we made certain adjustments to our consolidated balance sheets which consisted of an increase of $98.9 million in Convertible Senior Notes (the 2027 Notes as defined in Note 10 ), a decrease of $108.5 million in Additional Paid-in Capital and a decrease of $9.7 million in Accumulated Deficit. Additionally, from January 1, 2021, we will no longer incur non-cash interest expense for the amortization of debt discount after adoption, therefore the interest expense for the 2027 Notes, which is included in the “interest expense” on the condensed consolidated statements of operations and comprehensive loss, will be lower compared to fiscal year 2020.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Our revenue is primarily generated from U.S. customers. Our product and collaboration revenue is generated from the Product Segment, and our service revenue is generated from the Service Segment ( Note 14 ). The following tables present our revenues disaggregated by the timing of transfer of goods or services: Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 (in thousands) Product Revenue Collaboration Revenue Service Revenue Total Product Revenue Collaboration Revenue Service Revenue Total Timing of revenue recognition: Transferred at a point in time $ 18,296 $ — $ 166 $ 18,462 $ 46,982 $ — $ 379 $ 47,361 Transferred over time — 1,129 154 1,283 — 4,034 453 4,487 Total $ 18,296 $ 1,129 $ 320 $ 19,745 $ 46,982 $ 4,034 $ 832 $ 51,848 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 (in thousands) Product Revenue Collaboration Revenue Service Revenue Total Product Revenue Collaboration Revenue Service Revenue Total Timing of revenue recognition: Transferred at a point in time $ 2,819 $ — $ — $ 2,819 $ 2,868 $ — $ — $ 2,868 Transferred over time — 808 208 1,016 — 1,116 208 1,324 Total $ 2,819 $ 808 $ 208 $ 3,835 $ 2,868 $ 1,116 $ 208 $ 4,192 Product Revenue For the three and nine months ended September 30, 2021, all product revenue was generated from the sale of the RHA® Collection of dermal fillers. Receivables and contract liabilities from contracts with our product revenue customers are as follows: September 30, December 31, (in thousands) 2021 2020 Accounts receivables, net $ 1,577 $ 1,687 Contract liabilities: Deferred revenue, current $ (1,617) $ — Total contract liabilities $ (1,617) $ — Collaboration Revenue Viatris Collaboration and License Agreement Agreement Terms We entered into a collaboration and license agreement with Viatris (the “Viatris Collaboration”) in February 2018, pursuant to which we are collaborating with Viatris exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize an onabotulinumtoxinA biosimilar. Viatris has paid us an aggregate of $60 million in non-refundable fees as of September 30, 2021, and the agreement provides for additional remaining contingent payments of up to $70 million upon the achievement of certain clinical and regulatory milestones and up to $225 million upon specified, tiered sales milestones. The payments do not represent a financing component for the transfer of goods or services. In addition, Viatris is required to pay us low to mid-double digit royalties on any sales of the biosimilar in the U.S., mid-double digit royalties on any sales in Europe, and high single digit royalties on any sales in other ex-U.S. Viatris territories. However, we have agreed to waive royalties for U.S. sales, up to a maximum of $50 million in annual sales, during the first approximately four years after commercialization to defray launch costs. Revenue Recognition We re-evaluate the transaction price at each reporting period. We estimated the transaction price for the Viatris Collaboration using the most likely amount method. In order to determine the transaction price, we evaluated all of the payments to be received during the duration of the contract, which included milestones and consideration payable by Viatris. Other than the upfront payment, all other milestones and consideration we may earn under the Viatris Collaboration are subject to uncertainties related to development achievements, Viatris’ rights to terminate the agreement, and estimated effort for cost-sharing payments. Components of such estimated effort for cost-sharing payments include both internal and external costs. Consequently, the transaction price does not include any milestones and considerations that, if included, could result in a probable significant reversal of revenue when related uncertainties become resolved. Sales-based milestones and royalties are not included in the transaction price until the sales occur because the underlying value relates to the license and the license is the predominant feature in the Viatris Collaboration. As of September 30, 2021, the transaction price allocated to the unfulfilled performance obligations was $100.3 million. We recognize revenue and estimate deferred revenue based on the cost of development service incurred over the total estimated cost of development service to be provided for the development period. For revenue recognition purposes, the development period is estimated to continue through 2025. It is possible that this period will change and is assessed at each reporting date. For the three and nine months ended September 30, 2021, we recognized revenue related to development services of $1.1 million and $4.0 million, respectively. For the three and nine months ended September 30, 2020, we recognized revenue related to development services of $0.8 million and $1.1 million, respectively. Fosun License Agreement Agreement Terms In December 2018, we entered into a license agreement (the “Fosun License Agreement”) with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”), whereby we granted Fosun the exclusive rights to develop and commercialize DaxibotulinumtoxinA for Injection in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights. Fosun has paid us non-refundable upfront and other payments totaling $31 million before foreign withholding taxes. We are also eligible to receive (i) additional remaining contingent payments of up to $229.5 million upon the achievement of certain milestones based on (a) the approval of BLAs for certain aesthetic and therapeutic indications and (b) first calendar year net sales, and (ii) tiered royalty payments in low double digits to high teen percentages on annual net sales. The royalty percentages are subject to reduction in the event that (i) we do not have any valid and unexpired patent claims that cover the product in the Fosun Territory, (ii) biosimilars of the product are sold in the Fosun Territory or (iii) Fosun needs to pay compensation to third parties to either avoid patent infringement or market the product in the Fosun Territory. Revenue Recognition We estimated the transaction price for the Fosun License Agreement using the most likely amount method. We evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered. We will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of September 30, 2021, the transaction price allocated to unfulfilled performance obligation was $31 million. For the three and nine months ended September 30, 2021 and 2020, no revenue was recognized from the Fosun License Agreement. Contract liabilities from contracts with our collaboration revenue customers are as follows: September 30, December 31, (in thousands) 2021 2020 Contract liabilities: Deferred revenue, current - Viatris $ 9,317 $ 7,851 Total contract liabilities, current $ 9,317 $ 7,851 Deferred revenue, non-current - Viatris $ 42,762 $ 46,299 Deferred revenue, non-current - Fosun 30,995 30,995 Total contract liabilities, non-current $ 73,757 $ 77,294 Changes in our contract liabilities from contracts with our collaboration revenue customers for the nine months ended September 30, 2021 are as follows: (in thousands) Balance on January 1, 2021 $ 85,145 Revenue recognized (4,034) Billings and adjustments, net 1,963 Balance on September 30, 2021 $ 83,074 Service Revenue On July 23, 2020, we completed the acquisition of all of the issued and outstanding shares of Hint, Inc. (d/b/a HintMD) (the “HintMD Acquisition”), and HintMD became a wholly owned subsidiary of Revance. Following the HintMD Acquisition, we began to offer customer payment processing and certain value-added services through the HintMD Platform to aesthetic practices. We also commercially launched OPUL™, the next-generation fintech platform (together with the HintMD Platform, the “Fintech Platform”), in October 2021. The Fintech Platform has not generated material revenue to date. Generally, revenue related to the payment processing service is recognized at a point in time, whereas revenue related to the value-added services is recognized over time. Receivables and contract assets from contracts with our service revenue customers are as follows: September 30, December 31, (in thousands) 2021 2020 Accounts receivables, net $ 81 $ 142 Contract assets: Contract assets, current $ 148 $ 30 Contract assets, non-current 359 85 Total contract assets $ 507 $ 115

Business Acquisition

Business Acquisition	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Business Acquisition	Business AcquisitionOn July 23, 2020, we completed the HintMD Acquisition, and HintMD became a wholly-owned subsidiary of Revance. The following supplemental unaudited pro forma financial information presents the combined results of operations for each of the periods presented, as if the HintMD Acquisition occurred on January 1, 2019. The pro forma financial information is presented for illustrative purposes only, based on currently available information and certain estimates and assumptions we believe are reasonable under the circumstances, and is not necessarily indicative of future results of operations or the results that would have been reported if the HintMD Acquisition had been completed on January 1, 2019. These results were not used as a part of our analysis of the financial results and performance of the business. These results are adjusted and do not include any anticipated synergies or other expected benefits of the acquisition. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2020 2020 Total revenue $ 3,863 $ 4,633 Net loss $ (83,008) $ (216,312) Significant non-recurring pro forma adjustments include the following: • Transaction costs of $3.9 million were assumed to have been incurred on January 1, 2019 and were recognized as if incurred in the first quarter of 2019. • Share-based compensation expense of $1.3 million was assumed to have been incurred on January 1, 2019 and was recognized as if incurred in the first quarter of 2019. Such share-based compensation was related to stock awards held by HintMD employees prior to July 23, 2020 that have been assumed and converted into our stock awards.

Cash Equivalents and Short-Term

Cash Equivalents and Short-Term Investments	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Cash Equivalents and Short-Term Investments	Cash Equivalents and Short-Term Investments The following table is a summary our cash equivalents and short-term investments: September 30, 2021 December 31, 2020 Unrealized in thousands Cost Loss Fair Value Cost Fair Value Money market funds $ 114,267 $ — $ 114,267 $ 267,130 $ 267,130 Commercial paper 124,914 — 124,914 113,446 113,446 Corporate bonds 21,593 (3) 21,590 — — Total cash equivalents and available-for-sale securities $ 260,774 $ (3) $ 260,771 $ 380,576 $ 380,576 Classified as: Cash equivalents $ 114,267 $ 277,629 Short-term investments 146,504 102,947 Total cash equivalents and available-for-sale securities $ 260,771 $ 380,576 As of September 30, 2021 and December 31, 2020, we have no other-than-temporary impairments on our available-for-sale securities and the contractual maturities of the available-for-sale securities are less than one-year.

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net The following table sets forth the intangible assets and the remaining useful lives for the intangible assets: September 30, 2021 December 31, 2020 (in thousands, except for in years) Weighted-Average Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Distribution rights 2.7 $ 32,334 $ (10,778) $ 21,556 3.4 $ 32,334 $ (4,715) $ 27,619 Developed technology 5.1 35,800 (5,161) 30,639 5.6 19,600 (1,362) 18,238 In-process research and development (1) N/A — — — N/A 16,200 — 16,200 Customer relationships 2.8 10,300 (3,004) 7,296 3.6 10,300 (1,072) 9,228 Tradename 0.0 100 (100) — 0.6 100 (42) 58 Total intangible assets $ 78,534 $ (19,043) $ 59,491 $ 78,534 $ (7,191) $ 71,343 (1) In-process research and development relates to the research and development of the payment facilitator (“PayFac”) technology to facilitate the processing of customer payments. During the nine months ended September 30, 2021, the in-process research and development assets were placed into service and reclassified as developed technology. Aggregate amortization expense for the intangible assets presented in the condensed consolidated statements of operations and comprehensive loss are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Amortization (1) $ 3,512 $ 2,565 $ 9,862 $ 3,239 Selling, general and administrative 653 — 1,990 — Total amortization expense $ 4,165 $ 2,565 $ 11,852 $ 3,239 (1) The amortization expense related to Distribution rights and Developed technology was recorded to “amortization” in the condensed consolidated statement of operations and comprehensive loss. Based on the amount of intangible assets subject to amortization as of September 30, 2021, the estimated amortization expense for each of the next five fiscal years and thereafter was as follows: Year Ending December 31, (in thousands) 2021 remaining three months $ 4,156 2022 16,625 2023 16,625 2024 10,837 2025 5,967 2026 and thereafter 5,281 Total $ 59,491

Inventories

Inventories	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventories	InventoriesAs of September 30, 2021, and December 31, 2020, we had inventories of $10.2 million and $5.9 million, respectively, which were comprised of finished goods related to purchased RHA® Collection of dermal fillers.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Balance Sheet Components	Balance Sheet Components Accruals and Other Current Liabilities Accruals and other current liabilities consist of the following: September 30, December 31, (in thousands) 2021 2020 Accruals related to: Compensation $ 23,478 $ 17,374 General expenses 7,448 6,683 Inventories 2,567 1,796 Clinical trials 2,528 3,726 Interest expense 629 1,887 Other current liabilities 2,237 1,472 Total $ 38,887 $ 32,938 Property and Equipment, net Property and equipment, net consists of the following: September 30, December 31, (in thousands) 2021 2020 Manufacturing equipment $ 20,160 $ 19,810 Platform and computer software (1) 9,240 6,360 Leasehold improvements 6,767 5,972 Computer equipment 3,823 1,768 Other construction in progress 2,268 1,539 Furniture and fixtures 1,844 1,541 Total property and equipment 44,102 36,990 Less: Accumulated depreciation and amortization (22,073) (19,491) Property and equipment, net $ 22,029 $ 17,499

Derivative Liability

Derivative Liability	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Derivative Liability	Derivative LiabilityIn 2012, we entered into a settlement agreement in which we are obligated to pay $4.0 million upon achieving regulatory approval for DaxibotulinumtoxinA for Injection or DaxibotulinumtoxinA Topical. We determined that such payment was a derivative instrument that requires fair value accounting as a liability and periodic fair value remeasurement until settled. The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor. As of September 30, 2021, the fair value of the derivative liability was $3.2 million, which was measured using a term of 0.1 years, a risk-free rate of 0.1% and a credit risk adjustment of 7.5%. As of December 31, 2020, the fair value of the derivative liability was $3.1 million, which was measured using a term of 0.5 years, a risk-free rate of 0.1% and a credit risk adjustment of 7.5%.

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	Leases We have non-cancelable operating leases for facilities for research, manufacturing, and administrative functions, and equipment. Our leases have original lease periods expiring between 2027 and 2034. Our facilities operating leases include one or more options to renew for 7 years to 14 years. As of September 30, 2021, the weighted average remaining lease term is 8.6 years. The monthly payments for the facility leases escalate over the facility lease term with the exception of a decrease in payments at the beginning of 2022. Our lease contracts do not contain termination options, residual value guarantees or restrictive covenants. The operating lease costs are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Operating lease cost $ 2,224 $ 1,460 $ 5,802 $ 4,310 Variable lease cost (1) 385 282 1,016 631 Total operating lease costs $ 2,609 $ 1,742 $ 6,818 $ 4,941 (1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred. As of September 30, 2021, maturities of our operating lease liabilities are as follows: Year Ending December 31, (in thousands) 2021 remaining three months $ 2,539 2022 8,298 2023 8,468 2024 8,723 2025 8,981 2026 and thereafter 26,389 Total operating lease payments 63,398 Less imputed interest (1) (18,103) Present value of operating lease payments $ 45,295 (1) Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of 9.8%, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. Supplemental cash flow information related to the operating leases was as follows: Nine Months Ended September 30, (in thousands) 2021 2020 Cash paid for amounts included in the measurement of operating lease liabilities $ 7,956 $ 5,071 Right-of-use assets obtained in exchange for operating lease liabilities $ 18,855 $ 723 Leases Not Yet Commenced ABPS Fill-and-finish Line In December 2020, we entered into Amendment No.1 to the Technology Transfer, Validation and Commercial Fill/Finish Services Agreement with Ajinomoto Althea, Inc. dba Aji Bio-Pharma Services, a contract development and manufacturing organization (“ABPS”) (the “ABPS Amendment”). The ABPS Amendment contains a lease related to a dedicated fill-and finish-line for the manufacturing of DaxibotulinumtoxinA for Injection because it has an identified asset that is physically distinct for which we will have the right of control as defined under ASC 842. The right of control is conveyed because the embedded lease will provide us with both (1) the right to obtain substantially all of the economic benefit from the fill-and-finish line resulting from the exclusivity of the dedicated manufacturing capacity and (2) the right to direct the use of the fill-and-finish line through our purchase orders to ABPS. The embedded lease had not yet commenced as of September 30, 2021. The commencement and recognition of the right-of-use lease asset and lease liabilities related to this embedded lease will take place when we have substantively obtained the right of control, which is expected to be in January 2022. Under the ABPS Amendment, we are subject to remaining minimum purchase obligations of $3 million for the year ending in December 31, 2021, and $30 million for each of the years ending December 31, 2022, 2023 and 2024. Each party has the right to terminate the ABPS Amendment, without cause, with an 18-month written notice to the other party. LSNE Agreement In April 2021, we and Lyophilization Services of New England, Inc. (“LSNE”), a contract development and manufacturing services organization, entered into a commercial supply agreement (the “LSNE Agreement”) pursuant to which LSNE would serve as a non-exclusive manufacturer and supplier of our anticipated products currently under development (the “Products”). The initial term of the LSNE Agreement is dependent upon the date of regulatory submission for the applicable Product and may be terminated by either party in accordance with the terms of the LSNE Agreement. The term of the LSNE Agreement may also be extended for one additional three-year term upon mutual agreement of the parties. The LSNE Agreement contains a lease related to a dedicated fill-and finish-line for the manufacturing of the Products because it has identified assets that are physically distinct for which we will have the right of control as defined under ASC 842. The right of control is conveyed because the embedded lease will provide us with both (1) the right to obtain substantially all of the economic benefit from the fill-and-finish line resulting from the exclusivity implied from the dedicated manufacturing capacity and (2) the right to direct the use of the fill-and-finish line. The embedded lease has not yet commenced as of September 30, 2021. The commencement and recognition of the right-of-use lease assets and lease liabilities related to the embedded lease will take place when we have substantively obtained the right of control, which is currently expected to be in 2022. The embedded lease is preliminarily classified as a finance lease. Pursuant to the LSNE Agreement, we are responsible for certain costs associated with the design, equipment procurement and validation, and facilities-related costs, monthly payments and minimum purchase obligations throughout the initial term of the LSNE Agreement. Based on our best estimate as of September 30, 2021, our total commitment under the LSNE Agreement will be $20 million for 2022, $13 million for 2023, $18 million for 2024, $25 million for 2025 and $164 million for 2026 and thereafter in aggregate. Nashville Lease Expansion Premises In November 2020, we entered into a non-cancelable operating lease for an office space in Nashville, Tennessee (the “Nashville Lease”), which commenced and was recognized on the condensed consolidated balance sheets in June 2021. In July 2021, we entered into the Second Amendment to the Nashville Lease, which provides for the expansion of the initial premises to include an additional 30,591 square feet (the “Expansion Premises”) with an expected term to 2034. The lease commencement date of the Expansion Premises has not occurred and is expected to take place when the office space is made available to us after the completion of certain improvement work, which is currently expected in late 2022. The monthly base rent payments for the lease escalate over the term. The total undiscounted basic rent payments determinable for the Expansion Premises are $16 million with an expected term to 2034.

Convertible Senior Notes

Convertible Senior Notes	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Convertible Senior Notes	Convertible Senior Notes On February 14, 2020, we issued $287.5 million aggregate principal amount of convertible senior notes that are due in 2027 (the “2027 Notes”) pursuant to an indenture, dated February 14, 2020, between us and U.S. Bank National Association, as trustee (the “Indenture”). The 2027 Notes are senior unsecured obligations and bear interest at a rate of 1.75% per year, payable semiannually in arrears on February 15 and August 15 of each year, beginning on August 15, 2020. The 2027 Notes will mature on February 15, 2027, unless earlier converted, redeemed or repurchased. In connection with issuing the 2027 Notes, we received $278.3 million in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs. A portion of the net proceeds from the 2027 Notes were used to purchase the capped call transactions described below and the remainder will be used to fund expenses associated with commercial launch activities for both the RHA® Collection of dermal fillers and, if approved, DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines, research and development, and other corporate activities. The 2027 Notes may be converted at any time by the holders prior to the close of business on the business day immediately preceding November 15, 2026 only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending on June 30, 2020 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after November 15, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing circumstances. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. The conversion rate will initially be 30.8804 shares of our common stock per $1,000 principal amount of the 2027 Notes (equivalent to an initial conversion price of approximately $32.38 per share of our common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or if we deliver a notice of redemption, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2027 Notes in connection with such a corporate event or notice of redemption, as the case may be. Contractually, we may not redeem the 2027 Notes prior to February 20, 2024. We may redeem for cash all or any portion of the 2027 Notes, at our option, on or after February 20, 2024 if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2027 Notes. If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their 2027 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. Prior to adoption of ASU 2020-06 on January 1, 2021 ( Note 1 ), we separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was $175.4 million, which was calculated by using a discount rate of 9.5%, which was estimated to be our borrowing rate on the issuance date for a similar debt instrument without the conversion feature. The carrying amount of the equity component was $112.1 million, which represents the conversion option, and was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component of the 2027 Notes is included in additional paid-in capital in the condensed consolidated balance sheets and will not be subsequently remeasured as long as it continues to meet the conditions for equity classification. The difference between the principal amount of the 2027 Notes and the liability component (the “debt discount”) is amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss using the effective interest method over the term of the 2027 Notes. Total transaction costs for the issuance of the 2027 Notes were $9.2 million, consisting of the initial purchasers’ discount, commissions, and other issuance costs. Prior to adoption of ASU 2020-06 we allocated the total transaction costs proportionally to the liability and equity components. The transaction costs attributed to the liability component were $5.6 million, which were recorded as debt issuance costs (presented as contra debt in our condensed consolidated balance sheets) and are amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss over the term of the 2027 Notes. The transaction costs attributed to the equity component were $3.6 million, which were included in additional paid-in capital. As a result of the adoption of ASU 2020-06 ( Note 1 ), we reclassified the equity component associated with the 2027 Notes principal and transaction costs from the additional paid-in capital to the convertible senior notes on the condensed consolidated balance sheet. Debt discount was eliminated and the adjustment to the interest expenses was recorded in the accumulated deficit on the condensed consolidated balance sheets. Interest expense relating to the 2027 Notes in the condensed consolidated statements of operations and comprehensive loss are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Contractual interest expense $ 1,258 $ 1,258 $ 3,773 $ 3,159 Amortization of debt issuance costs 313 96 935 230 Amortization of debt discount (1) — 2,976 — 7,346 Total interest expense $ 1,571 $ 4,330 $ 4,708 $ 10,735 (1) The effective interest rate on the liability component of the 2027 Notes was 9.5% for the year ended December 31, 2020, which remained unchanged from the issuance date. As of December 31, 2020, the unamortized debt discount was $101.7 million, and will be amortized over 6.1 years. Due to the adoption of ASU 2020-06 ( Note 1 ), debt discount was eliminated on January 1, 2021 therefore we no longer amortize debt discount. As of September 30, 2021, and December 31, 2020, the convertible senior notes on the condensed consolidated balance sheet represented the carrying amount of the liability component of the 2027 Notes, net of unamortized debt discounts and debt issuance costs (as applicable), which are summarized as follows: (in thousands) September 30, 2021 December 31, 2020 2027 Notes $ 287,500 $ 287,500 Less: Unamortized debt issuance costs (7,181) (5,275) Less: Unamortized debt discount — (101,699) Carrying amount of 2027 Notes $ 280,319 $ 180,526 Capped Call Transactions Concurrently with the 2027 Notes, we entered into capped call transactions with one of the initial purchasers and another financial institution (the “option counterparties”) and used $28.9 million of the net proceeds from the 2027 Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce the potential dilutive effect upon conversion of the 2027 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2027 Notes, as the case may be, with such reduction and/or offset subject to a price cap of $48.88 of our common stock per share, which represents a premium of 100% over the last reported sale price of our common stock on February 10, 2020. The cap ped calls have an initial strike price of $32.38 per share, subject to certain adjustments, which corresponds to the conversion option strike price in the 2027 Notes. The capped call transactions cover, subject to anti-dilution adjustments, approximately 8.9 million shares of our common stock. The capped call transactions are separate transactions that we entered into with the option counterparties and are not part of the terms of the 2027 Notes. As the capped call transactions meet certain accounting criteria under ASC 815, the premium paid of $28.9 million was recorded as a reduction in additional paid-in capital in the condensed consolidated balance sheets, and will not be remeasured to fair value as long as the accounting criteria continue to be met. As of September 30, 2021, and December 31, 2020, we had not purchased any shares under the capped call transactions.

Stockholders' Equity and Stock-

Stockholders' Equity and Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders' Equity and Stock-Based Compensation	Stockholders’ Equity and Stock-Based Compensation 2014 Equity Incentive Plan (the “2014 EIP”) On January 1, 2021, the number of shares of common stock reserved for issuance under the 2014 EIP increased by 2,767,146 shares pursuant to the evergreen provision of the 2014 EIP. For the nine months ended September 30, 2021, 649,854 stock options and 1,421,257 restricted stock awards, including 234,350 performance stock awards, were granted under the 2014 EIP. As of September 30, 2021, 2,115,708 shares were available for issuance under the 2014 EIP. 2014 Inducement Plan (the “2014 IN”) For the nine months ended September 30, 2021, 104,090 restricted stock awards were granted under the 2014 IN. As of September 30, 2021, 610,867 shares were available for issuance under the 2014 IN. Hint, Inc. 2017 Equity Incentive Plan (the “HintMD Plan”) On July 23, 2020, we registered 1,260,946 shares of common stock under the HintMD Plan, which was assumed by the Company in connection with the HintMD Acquisition. For the nine months ended September 30, 2021, no stock options and no restricted stock awards were granted under the HintMD Plan. As of September 30, 2021, 444,520 shares of common stock were available for issuance under the HintMD Plan. 2014 Employee Stock Purchase Plan (the “2014 ESPP”) On January 1, 2021, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by 300,000 shares pursuant to the evergreen provision of the 2014 ESPP. As of September 30, 2021, 1,818,238 shares of common stock were available for issuance under the 2014 ESPP. Net Loss per Share Our basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, shares of common stock underlying the convertible senior notes at the initial conversion price, outstanding stock options, unvested restricted stock awards and performance stock awards were excluded from the computation of diluted net loss per share because including them would have been antidilutive. Common stock equivalents that were excluded from the computation of diluted net loss per share are presented below: September 30, 2021 2020 Convertible senior notes 8,878,938 8,878,938 Outstanding common stock options 4,898,630 5,783,695 Unvested restricted stock awards and performance stock awards 3,951,037 3,731,088 Shares of common stock expected to be purchased on December 31st under the 2014 ESPP 89,919 47,074 At-The-Market Offering In November 2020, we entered into a sales agreement with Cowen and Company, LLC (“Cowen”) as sales agent (the “2020 ATM Agreement”). Under the 2020 ATM Agreement, we may offer and sell, from time to time, through Cowen, shares of our common stock, having an aggregate offering price of up to $125 million. We are not obligated to sell any shares under the 2020 ATM Agreement. Subject to the terms and conditions of the 2020 ATM Agreement, Cowen will use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of The Nasdaq Global Market, to sell shares from time to time based upon our instructions, including any price, time or size limits specified by us. We pay Cowen a commission of up to 3% of the aggregate gross proceeds from each sale of shares of our common stock, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. The 2020 ATM Agreement may be terminated by Cowen or us at any time upon notice to the other party, or by Cowen at any time in certain circumstances, including the occurrence of a material and adverse change in our business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares. For the nine months ended September 30, 2021, we sold 761,526 shares of common stock under the 2020 ATM Agreement at a weighted average price of $29.09 per share, resulting in net proceeds of $21.6 million after sales agent commissions and offering costs. No shares of common stock have been sold under the 2020 ATM Agreement since we filed our 2020 Form 10-K on February 25, 2021. For the year ended December 31, 2020, we sold 2,585,628 shares of common stock under the 2020 ATM Agreement at a weighted average price of $27.18 per share, resulting in net proceeds of $68.2 million after sales agent commissions and offering costs. As of September 30, 2021, we had $32.6 million available under the 2020 ATM Agreement. Stock-based Compensation Stock-based compensation expense was allocated as follows: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Selling, general and administrative $ 6,624 $ 7,695 $ 21,193 $ 16,566 Research and development 3,914 2,982 11,320 8,008 Total stock based compensation expense $ 10,538 $ 10,677 $ 32,513 $ 24,574

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy: September 30, 2021 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 114,267 $ 114,267 $ — $ — Commercial paper 124,914 — 124,914 — Corporate bonds 21,590 — 21,590 — Total assets measured at fair value $ 260,771 $ 114,267 $ 146,504 $ — Liabilities Derivative liability $ 3,179 $ — $ — $ 3,179 Total liabilities measured at fair value $ 3,179 $ — $ — $ 3,179 December 31, 2020 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 267,130 $ 267,130 $ — $ — Commercial paper 113,446 — 113,446 — Total assets measured at fair value $ 380,576 $ 267,130 $ 113,446 $ — Liabilities Derivative liability $ 3,081 $ — $ — $ 3,081 Total liabilities measured at fair value $ 3,081 $ — $ — $ 3,081 For Level 1 investments, we use quoted prices in active markets for identical assets to determine the fair value. For Level 2 investments, we use quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trades of or quotes on the same or similar securities. We do not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services. The following table summarizes the change in the fair value of our Level 3 financial instrument: (in thousands) Derivative Liability Fair value as of December 31, 2020 $ 3,081 Change in fair value 98 Fair value as of September 30, 2021 $ 3,179 The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment ( Note 8 ). Generally, increases or decreases in these unobservable inputs would result in a directionally similar impact to the fair value measurement of this derivative instrument. The significant unobservable inputs used in the fair value measurement of the product approval payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment. The fair value of the 2027 Notes ( Note 10

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Teoxane Agreement We entered into an exclusive distribution agreement (the “Teoxane Agreement”) with Teoxane SA in January 2020, pursuant to which Teoxane granted us the exclusive right to import, market, promote, sell and distribute Teoxane’s line of RHA® dermal fillers in exchange for 2,500,000 shares of our common stock and certain other commitments by us. The Teoxane Agreement is effective for a term of ten years from product launch in September 2020 and may be extended for a two-year period upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations during each year of the term and are required to meet certain minimum expenditure requirements in connection with commercialization efforts unless prevented by certain conditions such as manufacturing delays. Either party may terminate the Teoxane Agreement in the event of the insolvency of, or a material breach by, the other party, including certain specified breaches that include the right for Teoxane to terminate the Teoxane Agreement for our failure to meet the minimum purchase requirements or commercialization expenditure during specified periods, or for our breach of the exclusivity obligations under the Teoxane Agreement. Other Commitments Our commitment under the ABPS Amendment and the LSNE Agreement were discussed in Note 9 —Leases. Other Contingencies We are obligated to make a $2.0 million milestone payment to a developer of botulinum toxin, List Biological Laboratories, Inc. (“List Laboratories”) upon achievement of a certain regulatory milestone. As of September 30, 2021, the milestone had not been achieved. We are also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products. We entered into an asset purchase agreement with Botulinum Toxin Research Associates, Inc. (“BTRX”), under which we are obligated to pay up to $16.0 million to BTRX upon the satisfaction of milestones relating to our product revenue, intellectual property, and clinical and regulatory events. Indemnification We have standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to our technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments we are obligated to pay under other indemnification agreements is not determinable because it involves claims for indemnification that may be made against us in the future but have not been made. We have not yet incurred material costs to defend lawsuits or settle claims related to indemnification agreements. We have indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. For the nine months ended September 30, 2021, no amounts associated with the indemnification agreements have been recorded. Litigation In October 2021, Allergan, Inc. and Allergan Pharmaceuticals Ireland (collectively, “Allergan”) filed a complaint against us and ABPS, one of our manufacturing sources of DaxibotulinumtoxinA for Injection, in the United States District Court for the District of Delaware, alleging infringement of the following patents assigned and/or licensed to Allergan, U.S. Patent Nos. 11,033,625; 7,354,740; 8,409,828; 11,124,786; and 7,332,567. Allergan claims that our formulation for DaxibotulinumtoxinA for Injection and our and ABPS’s manufacturing process used to produce DaxibotulinumtoxinA for Injection infringes its patents. Allergan also asserted a patent with claims related to a substrate for use in a botulinum toxin detection assay. We dispute Allergan’s claims and intend to defend the matter vigorously. In November 2021, we filed a motion to dismiss, but we cannot be certain of whether the motion will be granted.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Information	Segment Information Reportable Segments We report segment information based on the management approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments. We have two reportable segments: the Product Segment and the Service Segment. Each reportable segment represents a component, or an operating segment, for which separate financial information is available that is utilized on a regular basis by our chief operating decision maker in determining resource allocations and performance evaluation. We also considered whether the identified operating segments should be further aggregated based on factors including economic characteristics, the nature of products and services, production processes, customer base, distribution methods, and regulatory environment; however, no such aggregation was made due to dissimilarity of the operating segments. Product Segment Our Product Segment refers to the business that includes the research and development of DaxibotulinumtoxinA for Injection for aesthetic and therapeutic indications, the RHA® Collection of dermal fillers, our onabotulinumtoxinA biosimilar program in partnership with Viatris, and the U.S. distribution of the RHA® Collection of dermal fillers. Our product and collaboration revenues and related expenses are included in Product Segment. Service Segment Our Service Segment refers to the business that includes the development and commercialization of the Fintech Platform. Corporate and other expenses include operating expense related to general and administrative expenses, depreciation and amortization, stock-based compensation, in-process research and development and intersegment elimination that are not used in evaluating the results of, or in allocating resources to, our segments. Intersegment revenue represents the revenue generated between the two segments. Intersegment revenue was $0.5 million and $0.8 million for the three and nine months ended September 30, 2021, respectively. There was no intersegment revenue for the three and nine months ended September 30, 2020. Reconciliation of Segment Revenue to Consolidated Revenue Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Revenue: Product Segment $ 19,425 $ 3,627 $ 51,016 $ 3,984 Service Segment 320 208 832 208 Total revenue $ 19,745 $ 3,835 $ 51,848 $ 4,192 Reconciliation of Segment Loss from Operations to Consolidated Loss from Operations Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Loss from operations: Product Segment $ (36,298) $ (46,243) $ (108,982) $ (115,649) Service Segment (4,155) (2,813) (12,178) (2,813) Corporate and other expenses (32,270) (28,072) (91,912) (76,731) Total loss from operations $ (72,723) $ (77,128) $ (213,072) $ (195,193) We do not evaluate performance or allocate resources based on segment asset data, and therefore such information is not presented.

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. Our condensed consolidated balance sheet for the year ended December 31, 2020 was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2021, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (the “SEC”), on February 25, 2021. Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. All intercompany transactions have been eliminated.
Use of Estimates & Risks and Uncertainties	Use of Estimates & Risks and Uncertainties The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, the fair value of assets and liabilities assumed in business combinations, the incremental borrowing rate used to measure operating lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, the period of benefit associated with deferred costs, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals for clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, the fair value of derivative liability, and income taxes. The full extent of the impact of the COVID-19 pandemic on the Company’s future operational and financial performance is currently uncertain. The ongoing COVID-19 pandemic has caused a global slowdown of economic activity which has negatively impacted consumer spending, including with respect to our current and potential customers, while also disrupting sales channels and marketing activities. The extent to which the COVID-19 pandemic will further directly or indirectly impact our business, results of operations, financial condition, and liquidity will depend on future developments that are highly uncertain, including variant strains of the virus and the degree of their vaccine resistance and as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects. The FDA was previously unable to conduct the required inspection of our manufacturing facility in Northern California, due to the FDA’s travel restrictions associated with the COVID-19 pandemic. Although the FDA inspection process has taken place and we have responded to the FDA’s observations from the inspection, we cannot be certain of how long it will take to remediate deficiencies identified by the FDA during the inspection and respond to the FDA or how quickly or successfully the regulatory approval process will move following our remediation of the deficiencies and our response to the FDA or the future impact of the COVID-19 pandemic on the submissions related to DaxibotulinumtoxinA for Injection in indications outside of glabellar (frown) lines, the progress of clinical trials, supplies and sales of the RHA® Collection of dermal fillers, demand for our products and other aspects of our operations.
Recently Adopted Accounting Pronouncement	Recently Adopted Accounting Pronouncement In August 2020, the Financial Accounting Standards Board issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 simplifies the accounting for convertible debt instruments by removing certain requirements to separately account for conversion options embedded in debt instruments that are not required to be accounted for as derivative instruments. ASU 2020-06 also updates and improves the consistency of earnings per share calculations for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. On January 1, 2021, we adopted ASU 2020-06 using the modified retrospective method, and the adoption did not have any impact on our consolidated balance sheets as of December 31, 2020. As a result of the adoption, on January 1, 2021, we made certain adjustments to our consolidated balance sheets which consisted of an increase of $98.9 million in Convertible Senior Notes (the 2027 Notes as defined in Note 10 ), a decrease of $108.5 million in Additional Paid-in Capital and a decrease of $9.7 million in Accumulated Deficit. Additionally, from January 1, 2021, we will no longer incur non-cash interest expense for the amortization of debt discount after adoption, therefore the interest expense for the 2027 Notes, which is included in the “interest expense” on the condensed consolidated statements of operations and comprehensive loss, will be lower compared to fiscal year 2020.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables present our revenues disaggregated by the timing of transfer of goods or services: Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 (in thousands) Product Revenue Collaboration Revenue Service Revenue Total Product Revenue Collaboration Revenue Service Revenue Total Timing of revenue recognition: Transferred at a point in time $ 18,296 $ — $ 166 $ 18,462 $ 46,982 $ — $ 379 $ 47,361 Transferred over time — 1,129 154 1,283 — 4,034 453 4,487 Total $ 18,296 $ 1,129 $ 320 $ 19,745 $ 46,982 $ 4,034 $ 832 $ 51,848 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 (in thousands) Product Revenue Collaboration Revenue Service Revenue Total Product Revenue Collaboration Revenue Service Revenue Total Timing of revenue recognition: Transferred at a point in time $ 2,819 $ — $ — $ 2,819 $ 2,868 $ — $ — $ 2,868 Transferred over time — 808 208 1,016 — 1,116 208 1,324 Total $ 2,819 $ 808 $ 208 $ 3,835 $ 2,868 $ 1,116 $ 208 $ 4,192
Receivables and Contract Liabilities from Contract with Customer	Receivables and contract liabilities from contracts with our product revenue customers are as follows: September 30, December 31, (in thousands) 2021 2020 Accounts receivables, net $ 1,577 $ 1,687 Contract liabilities: Deferred revenue, current $ (1,617) $ — Total contract liabilities $ (1,617) $ — Contract liabilities from contracts with our collaboration revenue customers are as follows: September 30, December 31, (in thousands) 2021 2020 Contract liabilities: Deferred revenue, current - Viatris $ 9,317 $ 7,851 Total contract liabilities, current $ 9,317 $ 7,851 Deferred revenue, non-current - Viatris $ 42,762 $ 46,299 Deferred revenue, non-current - Fosun 30,995 30,995 Total contract liabilities, non-current $ 73,757 $ 77,294 Changes in our contract liabilities from contracts with our collaboration revenue customers for the nine months ended September 30, 2021 are as follows: (in thousands) Balance on January 1, 2021 $ 85,145 Revenue recognized (4,034) Billings and adjustments, net 1,963 Balance on September 30, 2021 $ 83,074 Receivables and contract assets from contracts with our service revenue customers are as follows: September 30, December 31, (in thousands) 2021 2020 Accounts receivables, net $ 81 $ 142 Contract assets: Contract assets, current $ 148 $ 30 Contract assets, non-current 359 85 Total contract assets $ 507 $ 115

Business Acquisition (Tables)

Business Acquisition (Tables)	9 Months Ended
	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Other Expected Benefits of Acquisition	These results are adjusted and do not include any anticipated synergies or other expected benefits of the acquisition. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2020 2020 Total revenue $ 3,863 $ 4,633 Net loss $ (83,008) $ (216,312)

Cash Equivalents and Short-Te_2

Cash Equivalents and Short-Term Investments (Tables)	9 Months Ended
	Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities	The following table is a summary our cash equivalents and short-term investments: September 30, 2021 December 31, 2020 Unrealized in thousands Cost Loss Fair Value Cost Fair Value Money market funds $ 114,267 $ — $ 114,267 $ 267,130 $ 267,130 Commercial paper 124,914 — 124,914 113,446 113,446 Corporate bonds 21,593 (3) 21,590 — — Total cash equivalents and available-for-sale securities $ 260,774 $ (3) $ 260,771 $ 380,576 $ 380,576 Classified as: Cash equivalents $ 114,267 $ 277,629 Short-term investments 146,504 102,947 Total cash equivalents and available-for-sale securities $ 260,771 $ 380,576

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Acquired Finite-lived Intangible Assets by Major Class	The following table sets forth the intangible assets and the remaining useful lives for the intangible assets: September 30, 2021 December 31, 2020 (in thousands, except for in years) Weighted-Average Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Distribution rights 2.7 $ 32,334 $ (10,778) $ 21,556 3.4 $ 32,334 $ (4,715) $ 27,619 Developed technology 5.1 35,800 (5,161) 30,639 5.6 19,600 (1,362) 18,238 In-process research and development (1) N/A — — — N/A 16,200 — 16,200 Customer relationships 2.8 10,300 (3,004) 7,296 3.6 10,300 (1,072) 9,228 Tradename 0.0 100 (100) — 0.6 100 (42) 58 Total intangible assets $ 78,534 $ (19,043) $ 59,491 $ 78,534 $ (7,191) $ 71,343 (1) In-process research and development relates to the research and development of the payment facilitator (“PayFac”) technology to facilitate the processing of customer payments. During the nine months ended September 30, 2021, the in-process research and development assets were placed into service and reclassified as developed technology.
Schedule of Acquired Indefinite-lived Intangible Assets by Major Class	The following table sets forth the intangible assets and the remaining useful lives for the intangible assets: September 30, 2021 December 31, 2020 (in thousands, except for in years) Weighted-Average Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Remaining Useful Lives Gross Carrying Amount Accumulated Amortization Net Carrying Amount Distribution rights 2.7 $ 32,334 $ (10,778) $ 21,556 3.4 $ 32,334 $ (4,715) $ 27,619 Developed technology 5.1 35,800 (5,161) 30,639 5.6 19,600 (1,362) 18,238 In-process research and development (1) N/A — — — N/A 16,200 — 16,200 Customer relationships 2.8 10,300 (3,004) 7,296 3.6 10,300 (1,072) 9,228 Tradename 0.0 100 (100) — 0.6 100 (42) 58 Total intangible assets $ 78,534 $ (19,043) $ 59,491 $ 78,534 $ (7,191) $ 71,343 (1) In-process research and development relates to the research and development of the payment facilitator (“PayFac”) technology to facilitate the processing of customer payments. During the nine months ended September 30, 2021, the in-process research and development assets were placed into service and reclassified as developed technology.
Schedule of Intangible Assets Amortization Expense	Aggregate amortization expense for the intangible assets presented in the condensed consolidated statements of operations and comprehensive loss are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Amortization (1) $ 3,512 $ 2,565 $ 9,862 $ 3,239 Selling, general and administrative 653 — 1,990 — Total amortization expense $ 4,165 $ 2,565 $ 11,852 $ 3,239 (1) The amortization expense related to Distribution rights and Developed technology was recorded to “amortization” in the condensed consolidated statement of operations and comprehensive loss.
Schedule of Finite-lived Intangible Assets, Future Amortization Expense	Based on the amount of intangible assets subject to amortization as of September 30, 2021, the estimated amortization expense for each of the next five fiscal years and thereafter was as follows: Year Ending December 31, (in thousands) 2021 remaining three months $ 4,156 2022 16,625 2023 16,625 2024 10,837 2025 5,967 2026 and thereafter 5,281 Total $ 59,491

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accruals and other current liabilities consist of the following: September 30, December 31, (in thousands) 2021 2020 Accruals related to: Compensation $ 23,478 $ 17,374 General expenses 7,448 6,683 Inventories 2,567 1,796 Clinical trials 2,528 3,726 Interest expense 629 1,887 Other current liabilities 2,237 1,472 Total $ 38,887 $ 32,938
Schedule of Property and Equipment, Net	Property and equipment, net consists of the following: September 30, December 31, (in thousands) 2021 2020 Manufacturing equipment $ 20,160 $ 19,810 Platform and computer software (1) 9,240 6,360 Leasehold improvements 6,767 5,972 Computer equipment 3,823 1,768 Other construction in progress 2,268 1,539 Furniture and fixtures 1,844 1,541 Total property and equipment 44,102 36,990 Less: Accumulated depreciation and amortization (22,073) (19,491) Property and equipment, net $ 22,029 $ 17,499

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Operating Lease Costs	The operating lease costs are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Operating lease cost $ 2,224 $ 1,460 $ 5,802 $ 4,310 Variable lease cost (1) 385 282 1,016 631 Total operating lease costs $ 2,609 $ 1,742 $ 6,818 $ 4,941 (1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.
Operating Lease Liability Maturities	As of September 30, 2021, maturities of our operating lease liabilities are as follows: Year Ending December 31, (in thousands) 2021 remaining three months $ 2,539 2022 8,298 2023 8,468 2024 8,723 2025 8,981 2026 and thereafter 26,389 Total operating lease payments 63,398 Less imputed interest (1) (18,103) Present value of operating lease payments $ 45,295
Supplemental Cash Flow Information	Supplemental cash flow information related to the operating leases was as follows: Nine Months Ended September 30, (in thousands) 2021 2020 Cash paid for amounts included in the measurement of operating lease liabilities $ 7,956 $ 5,071 Right-of-use assets obtained in exchange for operating lease liabilities $ 18,855 $ 723

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Convertible Debt	Interest expense relating to the 2027 Notes in the condensed consolidated statements of operations and comprehensive loss are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Contractual interest expense $ 1,258 $ 1,258 $ 3,773 $ 3,159 Amortization of debt issuance costs 313 96 935 230 Amortization of debt discount (1) — 2,976 — 7,346 Total interest expense $ 1,571 $ 4,330 $ 4,708 $ 10,735 (1) The effective interest rate on the liability component of the 2027 Notes was 9.5% for the year ended December 31, 2020, which remained unchanged from the issuance date. As of December 31, 2020, the unamortized debt discount was $101.7 million, and will be amortized over 6.1 years. Due to the adoption of ASU 2020-06 ( Note 1 ), debt discount was eliminated on January 1, 2021 therefore we no longer amortize debt discount. As of September 30, 2021, and December 31, 2020, the convertible senior notes on the condensed consolidated balance sheet represented the carrying amount of the liability component of the 2027 Notes, net of unamortized debt discounts and debt issuance costs (as applicable), which are summarized as follows: (in thousands) September 30, 2021 December 31, 2020 2027 Notes $ 287,500 $ 287,500 Less: Unamortized debt issuance costs (7,181) (5,275) Less: Unamortized debt discount — (101,699) Carrying amount of 2027 Notes $ 280,319 $ 180,526

Stockholders' Equity and Stoc_2

Stockholders' Equity and Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share	Common stock equivalents that were excluded from the computation of diluted net loss per share are presented below: September 30, 2021 2020 Convertible senior notes 8,878,938 8,878,938 Outstanding common stock options 4,898,630 5,783,695 Unvested restricted stock awards and performance stock awards 3,951,037 3,731,088 Shares of common stock expected to be purchased on December 31st under the 2014 ESPP 89,919 47,074
Schedule of Stock-based Compensation Expense	Stock-based compensation expense was allocated as follows: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Selling, general and administrative $ 6,624 $ 7,695 $ 21,193 $ 16,566 Research and development 3,914 2,982 11,320 8,008 Total stock based compensation expense $ 10,538 $ 10,677 $ 32,513 $ 24,574

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Instruments	The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy: September 30, 2021 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 114,267 $ 114,267 $ — $ — Commercial paper 124,914 — 124,914 — Corporate bonds 21,590 — 21,590 — Total assets measured at fair value $ 260,771 $ 114,267 $ 146,504 $ — Liabilities Derivative liability $ 3,179 $ — $ — $ 3,179 Total liabilities measured at fair value $ 3,179 $ — $ — $ 3,179 December 31, 2020 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 267,130 $ 267,130 $ — $ — Commercial paper 113,446 — 113,446 — Total assets measured at fair value $ 380,576 $ 267,130 $ 113,446 $ — Liabilities Derivative liability $ 3,081 $ — $ — $ 3,081 Total liabilities measured at fair value $ 3,081 $ — $ — $ 3,081
Summary of Changes in Fair Value of Financial Instruments	The following table summarizes the change in the fair value of our Level 3 financial instrument: (in thousands) Derivative Liability Fair value as of December 31, 2020 $ 3,081 Change in fair value 98 Fair value as of September 30, 2021 $ 3,179

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Reconciliation of Segment Revenue to Consolidated Revenue	Reconciliation of Segment Revenue to Consolidated Revenue Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Revenue: Product Segment $ 19,425 $ 3,627 $ 51,016 $ 3,984 Service Segment 320 208 832 208 Total revenue $ 19,745 $ 3,835 $ 51,848 $ 4,192
Reconciliation of Segment Loss From Operations to Consolidated Loss From Operations	Reconciliation of Segment Loss from Operations to Consolidated Loss from Operations Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2021 2020 2021 2020 Loss from operations: Product Segment $ (36,298) $ (46,243) $ (108,982) $ (115,649) Service Segment (4,155) (2,813) (12,178) (2,813) Corporate and other expenses (32,270) (28,072) (91,912) (76,731) Total loss from operations $ (72,723) $ (77,128) $ (213,072) $ (195,193)

The Company and Summary of Si_3

The Company and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jan. 01, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Net loss	$ 74,376	$ 81,257	$ 218,212	$ 203,780
Working capital surplus	228,000		228,000
Accumulated Deficit	1,334,854		1,334,854			$ 1,126,293
Cash, cash equivalents, and short-term investments	$ 273,700		$ 273,700
Cumulative Effect, Period of Adoption, Adjustment
Property, Plant and Equipment [Line Items]
Accumulated Deficit					$ (9,700)
Convertible debt					98,900
Decrease in additional paid in capital					$ 108,500

Revenue -Revenues Disaggregated

Revenue -Revenues Disaggregated by Timing of Transfer of Goods or Services (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 19,745	$ 3,835	$ 51,848	$ 4,192
Transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	18,462	2,819	47,361	2,868
Transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	1,283	1,016	4,487	1,324
Product Revenue
Disaggregation of Revenue [Line Items]
Total revenue	18,296	2,819	46,982	2,868
Product Revenue | Transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	18,296	2,819	46,982	2,868
Product Revenue | Transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	0	0	0	0
Collaboration Revenue
Disaggregation of Revenue [Line Items]
Total revenue	1,129	808	4,034	1,116
Collaboration Revenue | Transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	0	0	0	0
Collaboration Revenue | Transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	1,129	808	4,034	1,116
Service Revenue
Disaggregation of Revenue [Line Items]
Total revenue	320	208	832	208
Service Revenue | Transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	166	0	379	0
Service Revenue | Transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	$ 154	$ 208	$ 453	$ 208

Revenue - Receivables and Contr

Revenue - Receivables and Contract Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Contract liabilities:
Non-refundable upfront payment	$ (83,074)	$ (85,145)
Product revenue
Disaggregation of Revenue [Line Items]
Accounts receivables, net	1,577	1,687
Contract liabilities:
Non-refundable upfront payment	$ (1,617)	$ 0

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Jan. 31, 2019
Disaggregation of Revenue [Line Items]
Non-refundable upfront payment	$ 83,074,000		$ 83,074,000		$ 85,145,000
Revenue recognized			4,034,000
Development Services
Disaggregation of Revenue [Line Items]
Revenues	1,100,000	$ 800,000	4,000,000	$ 1,100,000
Viatris
Disaggregation of Revenue [Line Items]
Non-refundable upfront payment	60,000,000		60,000,000
Contingent payments	70,000,000		70,000,000
Revenue maximum for receipt of tiered milestone payments			225,000,000
Revenue recognition annual sales			$ 50,000,000
Revenue recognition annual sales of maturity period			4 years
Remaining performance obligation	100,300,000		$ 100,300,000
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.
Disaggregation of Revenue [Line Items]
Contingent payments						$ 229,500,000
Remaining performance obligation	31,000,000		31,000,000
Revenue recognized	$ 0	$ 0	$ 0	$ 0

Revenue - Contract Liabilities

Revenue - Contract Liabilities from Contracts (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Contract liabilities:
Total contract liabilities, current	$ 10,941	$ 7,851
Deferred revenue, non-current	73,757	77,294
Viatris
Contract liabilities:
Total contract liabilities, current	9,317	7,851
Deferred revenue, non-current	42,762	46,299
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.
Contract liabilities:
Deferred revenue, non-current	$ 30,995	$ 30,995

Revenue - Changes in Our Contra

Revenue - Changes in Our Contract Liabilities from Contracts (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Revenue from Contract with Customer [Abstract]
Beginning balance	$ 85,145
Revenue recognized	(4,034)
Billings and adjustments, net	1,963
Ending balance	$ 83,074

Revenue - Contract Assets from

Revenue - Contract Assets from Contracts (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Contract assets:
Contract assets, current	$ 148	$ 30
Contract assets, non-current	359	85
Total contract assets	507	115
Service Revenue
Disaggregation of Revenue [Line Items]
Accounts receivables, net	$ 81	$ 142

Business Acquisition - Pro Form

Business Acquisition - Pro Forma Financial Information (Details) - HintMD - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
Business Acquisition [Line Items]
Total revenue	$ 3,863	$ 4,633
Net loss	$ (83,008)	$ (216,312)

Business Acquisition - Addition

Business Acquisition - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Mar. 31, 2019	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition [Line Items]
Share-based compensation expense	$ 10,538	$ 10,677		$ 32,513	$ 24,574
HintMD
Business Acquisition [Line Items]
Acquisition related costs			$ 3,900
Share-based compensation expense			$ 1,300

Cash Equivalents and Short-Te_3

Cash Equivalents and Short-Term Investments (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Cost	$ 260,774,000	$ 380,576,000
Unrealized Loss	(3,000)
Fair Value	260,771,000	380,576,000
Other-than-temporary impairments on available-for-sale securities	0	0
Cash equivalents
Debt Securities, Available-for-sale [Line Items]
Fair Value	114,267,000	277,629,000
Short-term investments
Debt Securities, Available-for-sale [Line Items]
Fair Value	146,504,000	102,947,000
Money market funds
Debt Securities, Available-for-sale [Line Items]
Cost	114,267,000	267,130,000
Unrealized Loss	0
Fair Value	114,267,000	267,130,000
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Cost	124,914,000	113,446,000
Unrealized Loss	0
Fair Value	124,914,000	113,446,000
Corporate bonds
Debt Securities, Available-for-sale [Line Items]
Cost	21,593,000	0
Unrealized Loss	(3,000)
Fair Value	$ 21,590,000	$ 0

Intangible Assets, net - Intang

Intangible Assets, net - Intangible Assets and the Remaining Useful Lives (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Acquired Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 78,534	$ 78,534
Accumulated Amortization	(19,043)	(7,191)
Total	59,491
Net Carrying Amount	59,491	71,343
In Process Research and Development
Acquired Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 0	$ 16,200
Distribution rights
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful lives	2 years 8 months 12 days	3 years 4 months 24 days
Finite-lived intangible assets, gross	$ 32,334	$ 32,334
Accumulated Amortization	(10,778)	(4,715)
Total	$ 21,556	$ 27,619
Developed technology
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful lives	5 years 1 month 6 days	5 years 7 months 6 days
Finite-lived intangible assets, gross	$ 35,800	$ 19,600
Accumulated Amortization	(5,161)	(1,362)
Total	$ 30,639	$ 18,238
Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful lives	2 years 9 months 18 days	3 years 7 months 6 days
Finite-lived intangible assets, gross	$ 10,300	$ 10,300
Accumulated Amortization	(3,004)	(1,072)
Total	$ 7,296	$ 9,228
Tradename
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted-average remaining useful lives	0 years	7 months 6 days
Finite-lived intangible assets, gross	$ 100	$ 100
Accumulated Amortization	(100)	(42)
Total	$ 0	$ 58

Intangible Assets, net - Amorti

Intangible Assets, net - Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization	$ 4,165	$ 2,565	$ 11,852	$ 3,239
Amortization
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization	3,512	2,565	9,862	3,239
Selling, general and administrative
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization	$ 653	$ 0	$ 1,990	$ 0

Intangible Assets, net - Expect

Intangible Assets, net - Expected Amortization Expense for the Unamortized Acquired Intangible Assets (Details) $ in Thousands	Sep. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021 remaining three months	$ 4,156
2022	16,625
2023	16,625
2024	10,837
2025	5,967
2026 and thereafter	5,281
Total	$ 59,491

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventories	$ 10,192	$ 5,876

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Compensation	$ 23,478	$ 17,374
General expenses	7,448	6,683
Inventories	2,567	1,796
Clinical trials	2,528	3,726
Interest expense	629	1,887
Other current liabilities	2,237	1,472
Total	$ 38,887	$ 32,938

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 44,102		$ 44,102		$ 36,990
Less: Accumulated depreciation and amortization	(22,073)		(22,073)		(19,491)
Property and equipment, net	22,029		22,029		17,499
Amortization expenses	4,165	$ 2,565	11,852	$ 3,239
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	20,160		20,160		19,810
Platform and computer software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	9,240		9,240		6,360
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	6,767		6,767		5,972
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,823		3,823		1,768
Other construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,268		2,268		1,539
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,844		1,844		$ 1,541
Platform software
Property, Plant and Equipment [Line Items]
Amortization expenses	$ 200		$ 400

Derivative Liability (Details)

Derivative Liability (Details) - Product Approval Payment Derivative - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Valeant Pharmaceuticals International, Inc.
Settlement And Termination [Line Items]
Nonrecurring milestone payment	$ 4
Medicis Pharmaceutical Corporation
Settlement And Termination [Line Items]
Fair value of derivative	$ 3.2	$ 3.1
Medicis Pharmaceutical Corporation | Measurement Input, Expected Term
Settlement And Termination [Line Items]
Fair value, measurement input, duration	1 month 6 days	6 months
Medicis Pharmaceutical Corporation | Measurement Input, Risk Free Interest Rate
Settlement And Termination [Line Items]
Fair value, measurement input (percent)	0.10%	0.10%
Medicis Pharmaceutical Corporation | Measurement Input, Entity Credit Risk
Settlement And Termination [Line Items]
Fair value, measurement input (percent)	7.50%	7.50%

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	1 Months Ended	9 Months Ended
	Apr. 30, 2021option_to_extend_lease_term	Sep. 30, 2021USD ($)	Jul. 31, 2021USD ($)ft²
Lessee, Lease, Description [Line Items]
Weighted average remaining lease term		8 years 7 months 6 days
Purchase obligation, to be paid, remainder of fiscal year		$ 3
Purchase obligation, to be paid, year one		30
Purchase obligation, to be paid, year two		30
Purchase obligation, to be paid, year three		$ 30
Term of written notice		18 months
Collaborative agreement, extended contractual period | option_to_extend_lease_term	1
Other commitment, to be paid, year one		$ 20
Other commitment, to be paid, year two		13
Other commitment, to be paid, year three		18
Other commitment, to be paid, year four		25
Other commitment, to be paid, after year four		$ 164
Minimum
Lessee, Lease, Description [Line Items]
Extended term of lease		7 years
Maximum
Lessee, Lease, Description [Line Items]
Extended term of lease		14 years
Nashville Lease - Expansion Premises
Lessee, Lease, Description [Line Items]
Area of square feet | ft²			30,591
Lessee, operating lease, lease not yet commenced, amount			$ 16
Lyophilization Services of New England, Inc.
Lessee, Lease, Description [Line Items]
Collaborative agreement, contractual period	3 years

Leases - Operating Lease Costs

Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Operating lease cost	$ 2,224	$ 1,460	$ 5,802	$ 4,310
Variable lease cost	385	282	1,016	631
Total operating lease costs	$ 2,609	$ 1,742	$ 6,818	$ 4,941

Leases - Operating Lease Liabil

Leases - Operating Lease Liability Maturities (Details) $ in Thousands	Sep. 30, 2021USD ($)
Leases [Abstract]
2021 remaining three months	$ 2,539
2022	8,298
2023	8,468
2024	8,723
2025	8,981
2026 and thereafter	26,389
Total operating lease payments	63,398
Less imputed interest	(18,103)
Present value of operating lease payments	$ 45,295
Weighted average discount rate (percent)	9.80%

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 7,956	$ 5,071
Right-of-use assets obtained in exchange for operating lease liabilities	$ 18,855	$ 723

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Details)	Feb. 14, 2020USD ($)trading_day$ / shares	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of convertible senior notes		$ 0	$ 287,500,000
Convertible Debt | 2027 Notes
Debt Instrument [Line Items]
Principal amount	$ 287,500,000
Stated percentage	1.75%
Proceeds from issuance of convertible senior notes	$ 278,300,000
Threshold trading days | trading_day	20
Threshold consecutive trading days | trading_day	30
Threshold percentage of stock price trigger	130.00%
Conversion ratio	0.0308804
Conversion price (in dollars per share) | $ / shares	$ 32.38
Redemption price, percentage	100.00%
Long-term debt	$ 175,400,000	$ 280,319,000		$ 180,526,000
Effective percentage	9.50%			9.50%
Carrying amount of equity component	$ 112,100,000
Debt issuance costs	9,200,000
Debt issuance costs, liability component	5,600,000
Debt issuance costs, equity component	$ 3,600,000
Convertible Debt | 2027 Notes | Debt Conversion Terms One
Debt Instrument [Line Items]
Threshold trading days | trading_day	20
Threshold consecutive trading days | trading_day	30
Threshold percentage of stock price trigger	130.00%
Convertible Debt | 2027 Notes | Debt Conversion Terms Two
Debt Instrument [Line Items]
Threshold trading days | trading_day	5
Threshold consecutive trading days | trading_day	10
Threshold percentage of stock trading price	98.00%

Convertible Senior Notes - Inte

Convertible Senior Notes - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Feb. 14, 2020
Debt Instrument [Line Items]
Contractual interest expense	$ 1,258	$ 1,258	$ 3,773	$ 3,159
Amortization of debt issuance costs	313	96	935	230
Amortization of debt discount	0	2,976	0	7,346
Total interest expense	1,571	$ 4,330	4,708	$ 10,735
Convertible Debt | 2027 Notes
Debt Instrument [Line Items]
Effective percentage					9.50%	9.50%
Unamortized discount	$ 0		$ 0		$ 101,699
Remaining discount amortization period					6 years 1 month 6 days

Convertible Senior Notes - Carr

Convertible Senior Notes - Carrying Amount of Liability Component (Details) - Convertible Debt - 2027 Notes - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Feb. 14, 2020
Debt Instrument [Line Items]
2027 Notes	$ 287,500	$ 287,500
Less: Unamortized debt issuance costs	(7,181)	(5,275)
Less: Unamortized debt discount	0	(101,699)
Carrying amount of 2027 Notes	$ 280,319	$ 180,526	$ 175,400

Convertible Senior Notes - Capp

Convertible Senior Notes - Capped Call Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Feb. 14, 2020	Sep. 30, 2021	Sep. 30, 2020
Debt Instrument [Line Items]
Payment of capped call transactions	$ 28,900	$ 0	$ 28,865
Price cap (in dollars per share)	$ 48.88
Premium percentage over sale price	100.00%
Number of shares subject to anti-dilution adjustments (in shares)	8.9
Convertible Debt | 2027 Notes
Debt Instrument [Line Items]
Conversion price (in dollars per share)	$ 32.38

Stockholders' Equity and Stoc_3

Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	7 Months Ended	9 Months Ended		12 Months Ended
	Nov. 30, 2020	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Jan. 01, 2021	Jul. 23, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues (in shares)		0
Proceeds from issuance of common stock in connection with at-the-market offerings, net of commissions			$ 21,706	$ 0
At the Market Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issuance sales agreement, authorized offering price, maximum	$ 125,000
Commission, percentage, maximum	3.00%
Stock issued during period, shares, new issues (in shares)			761,526		2,585,628
Proceeds from issuance of common stock in connection with at-the-market offerings, net of commissions			$ 21,600		$ 68,200
Stock issuance sales agreement, available offering		$ 32,600	$ 32,600
At the Market Offering | Weighted Average
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)		$ 29.09	$ 29.09		$ 27.18
2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		2,115,708	2,115,708			2,767,146
2014 Equity Incentive Plan | Share-based Payment Arrangement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)			649,854
2014 Equity Incentive Plan | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted under restricted stock awards (shares)			1,421,257
2014 Equity Incentive Plan | Performance-based Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted under restricted stock awards (shares)			234,350
2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		610,867	610,867
2014 Inducement Plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)			104,090
2017 Equity Incentive Plan, HintMD Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		444,520	444,520
Shares underlying stock options granted (in shares)			0
Shares granted under restricted stock awards (shares)			0
2017 Equity Incentive Plan, HintMD Plan | HintMD
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)							1,260,946
2014 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)						300,000
2014 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		1,818,238	1,818,238

Stockholders' Equity and Stoc_4

Stockholders' Equity and Stock-Based Compensation - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	8,878,938	8,878,938
Outstanding common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	4,898,630	5,783,695
Outstanding common stock options | 2014 Employee Stock Purchase Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	89,919	47,074
Unvested restricted stock awards and performance stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	3,951,037	3,731,088

Stockholders' Equity and Stoc_5

Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement, expense	$ 10,538	$ 10,677	$ 32,513	$ 24,574
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement, expense	6,624	7,695	21,193	16,566
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement, expense	$ 3,914	$ 2,982	$ 11,320	$ 8,008

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	$ 260,771	$ 380,576
Total liabilities measured at fair value	3,179	3,081
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	114,267	267,130
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	124,914	113,446
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	21,590
Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	3,179	3,081
Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	114,267	267,130
Total liabilities measured at fair value	0	0
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	114,267	267,130
Level 1 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 1 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Level 1 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	146,504	113,446
Total liabilities measured at fair value	0	0
Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 2 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	124,914	113,446
Level 2 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	21,590
Level 2 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Total liabilities measured at fair value	3,179	3,081
Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Level 3 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	$ 3,179	$ 3,081

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Convertible debt, fair value disclosures	$ 329,600	$ 326,200
Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value as of December 31, 2020	3,081
Change in fair value	98
Fair value as of September 30, 2021	$ 3,179

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	9 Months Ended
	Jan. 31, 2020	Sep. 30, 2021
Loss Contingencies [Line Items]
Indemnification liability recorded during the period		$ 0
Teoxane Agreement
Loss Contingencies [Line Items]
Issuance of common stock in connection with the Teoxane Agreement (in shares)	2,500,000
Collaborative agreement, contractual period		10 years
Collaborative agreements, contractual, extension period		2 years
List Laboratories | Product Approval Payment Derivative
Loss Contingencies [Line Items]
Accrued milestone obligations		$ 2,000,000
Botulinum Toxin Research Associates, Inc.
Loss Contingencies [Line Items]
Accrued milestone obligations		$ 16,000,000

Segment Information - Reconcili

Segment Information - Reconciliation of Segment Revenue to Consolidated Revenue (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)segment	Sep. 30, 2020USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment			2
Total revenue	$ 19,745,000	$ 3,835,000	$ 51,848,000	$ 4,192,000
Product Segment
Segment Reporting Information [Line Items]
Total revenue	19,425,000	3,627,000	51,016,000	3,984,000
Service Segment
Segment Reporting Information [Line Items]
Total revenue	320,000	208,000	832,000	208,000
Intersegment elimination
Segment Reporting Information [Line Items]
Total revenue	$ 500,000	$ 0	$ 800,000	$ 0

Segment Information - Reconci_2

Segment Information - Reconciliation of Segment Loss from Operations to Consolidated Loss from Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Total loss from operations	$ (72,723)	$ (77,128)	$ (213,072)	$ (195,193)
Corporate and other expenses
Segment Reporting Information [Line Items]
Total loss from operations	(32,270)	(28,072)	(91,912)	(76,731)
Product Segment | Operating Segments
Segment Reporting Information [Line Items]
Total loss from operations	(36,298)	(46,243)	(108,982)	(115,649)
Service Segment | Operating Segments
Segment Reporting Information [Line Items]
Total loss from operations	$ (4,155)	$ (2,813)	$ (12,178)	$ (2,813)